Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1

Interventions

Dexamethasone 10Cyclophosphamide 9Cytarabine 7venetoclax 6Vincristine 6Methotrexate 5blinatumomab 4Prednisone 4Inotuzumab Ozogamicin 4Doxorubicin 4Rituximab 3prednylidene 2pegaspargase 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2deltacortene 2Mercaptopurine 2Etoposide 2Decitabine 2Calcium Dobesilate 2trametinib 1ruxolitinib 1olverembatinib 1ofatumumab 1nilotinib 1navitoclax 1fludarabine 1capivasertib 1azathiopurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡